The US-China Biotech Trade War That Isn't

Latest stories From slop to non-slop: The new big AI theme is quantity Green batteries built on dirty dealings in Indonesia China bets refitted destroyers can hold line in US numbers race

Washington could not block that flow without telling its own industry to walk away from a third of the world's pipeline. John Crowley, CEO of the Biotechnology Innovation Organization, the industry's main US trade group, put it bluntly: “We cannot restrict our way to success.”

Beijing faces the mirror image. It has made biopharma a priority industry in its new five-year plan, yet the fastest way to turn a Chinese molecule into money is still a Western license, Western trials and FDA approval.

Cutting that off would starve the very firms the plan is meant to build. So Beijing's rule aims to stop the uprooting of core platforms while still letting companies earn from them. If the Treasury rule is finalized as drafted, it will redraw the business model rather than end the relationship. Three shifts follow.

First, value migrates from equity to royalties. American venture funds that have been building companies around Chinese science will lose the ability to hold stakes in the Chinese developers themselves. Chinese firms lose a class of investor but keep the licensing income.

There is an irony here. The rule locks out the early-stage American investors who take the most risk, while leaving multinationals free to treat China as a discounted research and development supermarket, buying finished candidates off the shelf. The science will continue; only the shareholder register will change.

Second, the early stage gets lonelier. Licensing works for assets that already have data. It does not pay for the first experiments. Restricting American money at the seed stage while keeping the licensing stage open will push Chinese biotech toward domestic state and private capital, which is exactly the self-reliance Beijing has been chasing for years.

Third, capital looks for a third address. Singapore, Seoul, Tokyo and Hong Kong may soon see funds restructured so that the entity holding a Chinese stake is not American. Treasury will try to reach such structures. The history of export controls suggests the chase is long.

The deeper question is whether the semiconductor template fits biology at all. Chip controls work because a handful of chokepoints exist: lithography machines, advanced nodes, design software. Biology has far fewer.

Treasury's draft defines biotechnology so broadly that it sweeps in vaccines, blood components, monoclonal antibodies and standard laboratory instruments, tools found in university labs worldwide. Even seasoned Washington analysts found the draft more aggressive than they had expected.

Even Treasury seems unsure. The proposal itself asks whether the restrictions could backfire by creating public health risks or harming American companies, and invites narrower alternatives. That is an unusual question to ask about a rule one has just written.

It reads less like settled doctrine and more like an opening position, in the same way the Trump administration has used tariffs. The trouble is that drug programs run for a decade. A deal structure chilled today decides which therapies exist in the mid-2030s, whatever the final text says.